Rivaroxaban

Brand names: Xarelto · Active ingredient: Rivaroxaban

In short: Rivaroxaban tablets, in combination with aspirin, are indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease. Rivaroxaban tablets, in combination with aspirin, are indicated to reduce the ri

Forms & strengths2.5 mg tablets: Yellow, round shape, biconvex coated tablet. Engraved "R" over "2.5" on one side, plain on the other side.
LabelApotex Corp.
Label updatedOct 26, 2026

What is Rivaroxaban used for?

Rivaroxaban tablets, in combination with aspirin, are indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease.

Rivaroxaban tablets, in combination with aspirin, are indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with PAD, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD.

âš  Boxed warning (FDA's strongest warning)

WARNING: (A) PREMATURE DISCONTINUATION OF

RIVAROXABAN TABLETS INCREASES THE

RISK OF THROMBOTIC EVENTS,

(B) SPINAL/EPIDURAL HEMATOMA

A. Premature discontinuation of

rivaroxaban tablets

increases the risk of thrombotic events

Premature discontinuation of any oral anticoagulant, including

rivaroxaban

tablets

, increases the risk of thrombotic events. If anticoagulation with

rivaroxaban tablets

is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant

.

B. Spinal/epidural hematoma

Epidural or spinal hematomas have occurred in patients treated with

rivaroxaban

who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

use of indwelling epidural catheters

concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants

a history of traumatic or repeated epidural or spinal punctures

a history of spinal deformity or spinal surgery

optimal timing between the administration of

rivaroxaban tablets and neuraxial procedures is not known

.

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary

. …

Rivaroxaban dosage

Table 1: Recommended Dosage in Adults

Indication | Renal Considerations* | Dosage | Food/Timing†

Reduction of Risk of Major Cardiovascular Events (CV Death, MI, and Stroke) in CAD | No dose adjustment needed based on CrCl | 2.5 mg twice daily, plus aspirin (75 to 100 mg) once daily | Take with or without food

Reduction of Risk of Major Thrombotic Vascular Events in PAD, Including Patients after Lower Extremity Revascularization due to Symptomatic PAD | No dose adjustment needed based on CrCl | 2.5 mg twice daily, plus aspirin (75 to 100 mg) once daily.

When starting therapy after a successful lower extremity revascularization procedure, initiate once hemostasis has been established. | Take with or without food

* Calculate CrCl based on actual weight .

†

.

Switching from Warfarin to Rivaroxaban Tablets - When switching patients from warfarin to rivaroxaban tablets, discontinue warfarin and start rivaroxaban tablets as soon as the International Normalized Ratio (INR) is below 3 in adults to avoid periods of inadequate anticoagulation.

Switching from Rivaroxaban Tablets to Warfarin –

Adults:

No clinical trial data are available to guide converting patients from rivaroxaban tablets to warfarin. Rivaroxaban tablets affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. One approach is to discontinue rivaroxaban tablets and begin both a parenteral anticoagulant and warfarin at the time the next dose of rivaroxaban tablets would have been taken.

Once rivaroxaban tablets are discontinued, INR testing may be done reliably 24 hours after the last dose.

Switching from Rivaroxaban Tablets to Anticoagulants other than Warfarin - For adult patients currently taking rivaroxaban tablets and transitioning to an anticoagulant with rapid onset, discontinue rivaroxaban tablets and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next rivaroxaban tablets dose would have been taken .

Switching from Anticoagulants other than Warfarin to Rivaroxaban Tablets - For adult patients currently receiving an anticoagulant other than warfarin, start rivaroxaban tablets 0 to 2 hours prior to the next scheduled administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. For unfractionated heparin being administered by continuous infusion, stop the infusion and start rivaroxaban tablets at the same time.

If anticoagulation must be discontinued to reduce the risk of bleeding with surgical or other procedures, rivaroxaban tablets should be stopped at least 24 hours before the procedure to reduce the risk of bleeding . …

How to take Rivaroxaban — instructions & advice from the label

For the tablets, advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).

Instructions for Patient Use

Advise patients to take rivaroxaban tablets only as directed.

Remind patients to not discontinue rivaroxaban tablets without first talking to their healthcare professional.

Adults

Advise patients who cannot swallow the tablet whole to crush rivaroxaban tablets and combine with a small amount of applesauce followed by food .

For patients requiring an NG tube or gastric feeding tube, instruct the patient or caregiver to crush the rivaroxaban tablet and mix it with a small amount of water before administering via the tube .

If a dose is missed, advise the patient according to the instructions in the Full Prescribing Information based on their dosing schedule .

Bleeding Risks

Advise patients to report any unusual bleeding or bruising to their physician. Inform patients that it might take them longer than usual to stop bleeding, and that they may bruise and/or bleed more easily when they are treated with rivaroxaban tablets . …

Warnings & precautions

Do not take this medicine if: Rivaroxaban tablets are contraindicated in patients with:

active pathological bleeding

severe hypersensitivity reaction to rivaroxaban tablets (e.g., anaphylactic reactions)

Premature discontinuation of any oral anticoagulant, including rivaroxaban tablets, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from rivaroxaban tablets to warfarin in clinical trials in another indication in patients. If rivaroxaban tablets are discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant .

Rivaroxaban tablets increase the risk of bleeding, including in any organ, and can cause serious or fatal bleeding. In deciding whether to prescribe rivaroxaban tablets to patients at increased risk of bleeding, the risk of thrombotic events should be weighed against the risk of bleeding.

Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue rivaroxaban tablets in patients with active pathological hemorrhage. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.

Concomitant use of other drugs that impair hemostasis increases the risk of bleeding. These include aspirin, P2Y12 platelet inhibitors, dual antiplatelet therapy, other antithrombotic agents, fibrinolytic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) , selective serotonin reuptake inhibitors, and serotonin norepinephrine reuptake inhibitors.

Concomitant use of drugs that are known combined P-gp and strong CYP3A inhibitors increases rivaroxaban exposure and may increase bleeding risk . …

Rivaroxaban side effects

The following clinically significant adverse reactions are also discussed in other sections of the labeling:

Increased Risk of Stroke After Discontinuation in Another Indication

Bleeding Risk

Spinal/Epidural Hematoma

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Hemorrhage

The most common adverse reactions with rivaroxaban tablets were bleeding complications .

Reduction of Risk of Major Cardiovascular Events in Patients with CAD

In the COMPASS trial overall, the most frequent adverse reactions associated with permanent drug discontinuation were bleeding events, with incidence rates of 2.7% for rivaroxaban 2.5 mg twice daily vs. 1.2% for placebo on background therapy for all patients with aspirin 100 mg once daily. The incidences of important bleeding events in the CAD and PAD populations in COMPASS were similar.

Table 10 shows the number of patients experiencing various types of major bleeding events in the COMPASS trial.

Table 10: Major Bleeding Events in COMPASS - On Treatment Plus 2 Days*

Parameter | Rivaroxaban

†

N=9,134

n (%/year) | Placebo

†

N=9,107

n (%/year) | Rivaroxaban vs. …

Drug interactions

Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters, the latter also known as breast cancer resistance protein (BCRP). Combined P-gp and strong CYP3A inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding. Combined P-gp and strong CYP3A inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events.

Interaction with Combined P-gp and Strong CYP3A Inhibitors

Avoid concomitant administration of rivaroxaban tablets with known combined P-gp and strong CYP3A inhibitors (e.g., ketoconazole and ritonavir) .

Although clarithromycin is a combined P-gp and strong CYP3A inhibitor, pharmacokinetic data suggests that no precautions are necessary with concomitant administration with rivaroxaban tablets as the change in exposure is unlikely to affect the bleeding risk .

Interaction with Combined P-gp and Moderate CYP3A Inhibitors in Patients with Renal Impairment

Rivaroxaban tablets should not be used in patients with CrCl 15 to <80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk . …

About this medicine

Rivaroxaban, USP, a factor Xa (FXa) inhibitor, is the active ingredient in rivaroxaban film coated tablets, USP with the chemical name 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide. The molecular formula of rivaroxaban, USP is C19H18ClN3O5S and the molecular weight is 435.88. The structural formula is:

Rivaroxaban, USP is a pure (S)-enantiomer. It is non-hygroscopic, white to off-white powder. Rivaroxaban, USP is slightly soluble in acetone and polyethylene glycol 400, and practically insoluble in water.

Each film-coated tablet contains 2.5 mg of rivaroxaban, USP. The inactive ingredients of rivaroxaban tablets, USP are: anhydrous lactose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and poloxamer. Additionally, the film-coating mixture contains ferric oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

FDA approved dissolution test method and specifications differ from USP.

How it works: Rivaroxaban tablets are a selective inhibitor of FXa. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e98f6d83-5172-97a1-ee41-5d7d1d8ba2fd. Read the full official label on DailyMed.

Related medicines

Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol